What top creators are saying about Hims & Hers Health, Inc.(HIMS)— Page 6

The stock's positive performance is attributed to the market positively 'digesting the news of the testosterone launch,' which is viewed as a significant and bullish catalyst for future growth.

The launch of TRT and at-home lab testing is a significant growth catalyst. The stock is considered undervalued ('super cheap') and 'highest quality in its sector', making it an attractive long-term investment despite high volatility.

Directly criticized by competitor Mark Cuban, who stated customers are 'getting ripped off,' highlighting significant competitive pressure from low-cost alternatives which could threaten its pricing power and margins.

Shows explosive growth and incredible stock performance, but its weak moat and operation in a high-risk industry (pharmaceuticals) warrant caution for long-term investors.

The investment thesis is strengthening as GLP-1 lawsuit risks fade and the company pivots to a new HRT market. The business has high recurring revenue, is cash-pay, and recession-resistant.

High volatility and short squeeze potential due to 35% short interest. Legal risks concerning GLP-1s may be overstated. A rumored testosterone product launch is a significant upcoming catalyst.

The stock rallied after a judge dismissed a lawsuit against a compounding pharmacy, which is viewed as a positive legal precedent for its business model.

The speaker is very bullish, viewing the high 34% short interest as a major miscalculation by Wall Street, creating a potential for a short squeeze. Catalysts include new treatments, international expansion, and a future generic semaglutide launch.

The company's business model targets large and expanding wellness markets (weight loss, mental health) through a convenient digital platform, which could be a significant growth driver.

A key player in the parallel market for weight loss drugs, representing a high-risk, high-reward opportunity. The company's future depends on its ability to navigate significant legal and regulatory challenges as its business model, built on a now-ended drug shortage, is in a 'regulatory gray area'.

The market is incorrectly viewing HIMS as only a GLP-1 company, while it is a diversified, disruptive telehealth platform with multiple growth catalysts, including new treatments (menopause, testosterone) and international expansion. The recent sell-off is seen as a buying opportunity.

Considered a 'steal' at $42, as the market is overly focused on perceived GLP-1 lawsuit risk while ignoring its diversified business model.

Faces a significant competitive threat from Novo Nordisk's Ozempic price cut, received a downgrade from Truist (price target lowered to $37), and the CEO has been selling shares.

Presented as a current bearish idea based on a combination of weakening business fundamentals (negative press, slowing growth) and a strong insider sell signal (a massive sale by the CEO).

Multiple insiders, including the CEO, made large, unscheduled sales totaling almost $40 million, which is a significant red flag suggesting a lack of confidence and potential for more negative news.

Mentioned as a past successful investment for the host and used as a valuation comparable, with the host noting it has a similarly 'cheap' valuation to KULR.

Sentiment is mixed to cautiously bearish due to a significant 'lawsuit overhang' from Novo Nordisk over its practice of selling compounded semaglutide. While the market leader, its growth has been revised down, and the end of a partnership with Novo Nordisk is expected to create a 'dent in the quarterly revenue'.

The CEO sold over $30 million worth of stock, which is considered a noteworthy bearish signal, suggesting the insider may see the current price as high or anticipate headwinds.

The CEO made his largest-ever, unscheduled sale of $5 million after a 200% stock run-up. This is a strong bearish signal suggesting he believes the stock is overvalued.

The host is extremely bullish, describing the stock as 'extremely, extremely compelling' and 'nearly a buy' even at a high price, with a more attractive valuation than PLTR or HOOD.

Mentioned as a competitor that also had weakness in its ED segment. While it's noted to have a better GLP-1 strategy, LifeMD is considered '2x cheaper'.

Considered a long-term bullish investment due to its recurring revenue subscription model and significant growth potential from expanding into large new markets like hormone health and longevity, which could lead to 'exponential growth'.

Considered the 'better play' compared to LifeMD due to its superior cash-pay model, which avoids insurance reimbursement risks and allows for faster reinvestment. The company is guiding for 45% revenue growth in 2025.

The speaker expressed disappointment that HIMS did not raise its guidance in its latest report, which is contrasted negatively with ODD's consistent raising of guidance. This highlights a negative sentiment based on recent performance.

The speaker is very bullish on the long-term vision for preventative care and AI-driven medicine. The stock is considered 'dirt cheap' based on its 2030 targets of $6.5 billion in revenue and $1.3 billion in EBITDA.

The host is very bullish long-term, viewing the post-earnings stock drop as a buying opportunity due to a 'stunning' long-term trajectory, strong growth metrics, and multiple future catalysts like international expansion (Canada), a new longevity product line, and Hormone Replacement Therapy.

Bearish sentiment following a lackluster earnings report that was a 'little light' and only affirmed guidance. The key concern is 'GLP uncertainty,' referring to the competitive threat from new weight-loss drugs.

The company's sale of 'technically illegal' compounded drugs is a 'painful drag' on Novo Nordisk and faces significant risk from potential swift FDA action to stop these sales.

Mentioned as a 'copycat' competitor that Novo Nordisk's management is focused on, but the analysis suggests they are the 'wrong threat' compared to the primary rival, Eli Lilly.

Stock recovered strongly as competitor Novo Nordisk blamed competition from compounders like Hims for its own poor outlook, which the market interprets as a major validation of the Hims business model.

Mentioned in the context of its recently terminated partnership with Novo Nordisk, which was related to the issue of compounded drugs.

Faced a potential regulatory headwind, but the stock recovered. The host, a shareholder, is holding his position and believes the negative news may be overblown.

The speaker is a long-term, bullish investor, viewing HIMS as the potential 'Netflix of healthcare' and believes the market is overly focused on the GLP-1 story, ignoring diversification and other positive catalysts.

The speaker holds a very long-term bullish thesis, believing Wall Street misunderstands its disruptive healthcare model. Despite extreme volatility and being heavily shorted, it is viewed as a long-term disruptor.

The stock was up over 11% and broke through $56, speculated to be due to its 38% short interest. Unlike other meme stocks, the host notes it is a 'good company underneath it'.

The speaker believes Eli Lilly's 'Lilly direct' program will disrupt competitors like Hims by selling directly to consumers, posing a significant threat to its business model.

The company is described as being in a 'high state of uncertainty' with 'no visibility on anything,' making it an asset to avoid due to the lack of a clear investment thesis.

The speaker has a 'big short, short position' in the stock and advises avoiding it because it's a company that people are 'generally over obsessed with.'

Presented as an example of a traditional company that could potentially outperform monetary debasement and Bitcoin's returns due to its hyper-growth characteristics.

Mentioned for its 'virtually one' correlation with Robinhood's stock chart, as an example for pairs trading, not for its own fundamentals.

The host is extremely bullish due to the 2026 Canadian expansion, which offers a first-mover advantage for generic semaglutide. This is seen as a major growth catalyst that could significantly move revenue and stock price.

The company announced expansion into Canada for 2026. The recent hiring of a former VP of Product from Robinhood is seen as a bullish sign for future product innovation.

The stock is down following a reiterated downgrade from Morgan Stanley, which cited significant, long-term legal risks from lawsuits by Eli Lilly.

Exceptionally bullish sentiment, calling it the position the speaker is 'most confident on'. The company is seen as a 'zero to one' disruptor with accelerating revenue growth, driven partly by GLP-1 drugs. Dips are viewed as buying opportunities.

The speaker is long-term bullish, viewing it as a superior investment to traditional pharma. The recent stock drop due to the Novo Nordisk partnership ending is seen as 'noise', given its dominant telehealth market share of nearly 50%.

The hiring of a former VP of Product from Robinhood is a major catalyst, signaling a focus on technology and shifting the narrative away from its previous reliance on a GLP-1 drug partnership.

Hired a former Robinhood VP as its first Chief Product Officer, a move seen as a signal that the company is transforming into a tech-focused company. The stock is heavily shorted, creating potential for a short squeeze.

Extremely bullish outlook, viewed as a disruptive, customer-obsessed company that will become a 'special company'. The hiring of a new CPO from Robinhood is seen as a major catalyst.

The stock is facing significant business and reputational risk after partner Novo Nordisk terminated its collaboration and publicly accused the company of illegal and deceptive practices, causing a 32% drop in the stock price.

The hiring of a new Chief Product Officer from Robinhood is seen as a very bullish signal, reinforcing its identity as a tech-focused healthcare company and strengthening the long-term investment thesis.